Introduction: To mirror guideline-adherence for pT1 bladder cancer treatment in Northern Germany. Materials and Methods: Overall, 111 patients with pT1 diagnosis were treated at 4 institutions. Guideline-adherence was defined as repeat resection, instillation, and quarterly cystoscopy. Patient characteristics and pathological parameters were assessed. We summarized patients using descriptive analyses and evaluated guideline-adherence within selected subgroups. We created a multivariable model to identify predictors of guideline-adherence. Results: Median age was 75 years (range 39–94 years), multifocal tumors were found in 44.1%, early instillation was performed in 33.3%, and repeat resection was performed in 77.5%. Of 62.2% who underwent instillation, 59.4% received BCG, while 40.6% received Mitomycin C or other agents. Cystoscopic follow-up was performed in 81.8%. Guideline-adherence was met in 56.8%. Patients aged below the median met adherence metrics more often compared to those above the median (66.7 vs. 46.3%; p = 0.030). Men more frequently met adherence metrics compared to women (62.1 vs. 37.5%; p = 0.038). More patients with multifocal tumors met all 3 adherence metrics (69.4 vs. 48.0%; p = 0.050), as compared to those with unifocal lesions. In multivariable analyses, age-adjusted comorbidity (OR 0.75; 95% CI 0.59–0.94; p = 0.011) and multifocality (OR 2.62; 95% CI 1.09–6.27; p = 0.031) were predictors of guideline-adherence. Conclusions: We found non-adherence in more than one-third of patients and disparities among patients of different age and according to tumor focality. Larger samples and prospective studies are needed to delineate and eradicate treatment disadvantages in these high-risk patients.

Keywords:
BCG Vaccine, Guideline adherence, Instillation, Drug, Quality of health care, Urinary bladder neoplasms
1.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C et al: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr (accessed on February 2, 2018).
2.
Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM, et al: EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 2017; 71: 447–461.
3.
Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al: Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49: 466–465; discussion 475–467.
4.
Power NE, Izawa J: Comparison of guidelines on non-muscle invasive bladder cancer (EAU, CUA, AUA, NCCN, NICE). Bladder Cancer 2016; 2: 27–36.
5.
Hendricksen K, Aziz A, Bes P, Chun FK, -Dobruch J, Kluth LA, et al: Discrepancy -between european association of urology guidelines and daily practice in the management of non-muscle-invasive bladder cancer: results of a European survey. Eur Urol Focus 2017 2017:pii:S2405-4569(17)30206-7.
6.
Lebentrau S, Lebentrau J, May M, Wick AK, Mathew M, Schostak M: [Results of a questionnaire-based study on guideline adherence regarding adjuvant treatment recommendations for patients with non-muscle-invasive bladder cancer: just a disturbing sidelight?]. Aktuelle Urol 2016; 47: 408–413.
7.
van Rhijn BW, Burger M: Bladder cancer: low adherence to guidelines in non-muscle-invasive disease. Nat Rev Urol 2016; 13: 570–571.
8.
Witjes JA, Palou J, Soloway M, Lamm D, Kamat AM, Brausi M, et al: Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guerin (BCG): results of an international individual patient data survey (IPDS). BJU Int 2013; 112: 742–750.
9.
Epstein JI, Amin MB, Reuter VR, Mostofi FK: The world health organization/international society of urological pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998; 22: 1435–1448.
10.
Vetterlein MW, Roschinski J, Gild P, Marks P, Soave A, Doh O, et al: Impact of the Ki-67 labeling index and p53 expression status on disease-free survival in pT1 urothelial carcinoma of the bladder. Transl Androl Urol 2017; 6: 1018–1026.
11.
Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al:: Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol 2016; 196: 1021–1029.
12.
Divrik RT, Yildirim U, Zorlu F, Ozen H: The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol 2006; 175: 1641–1644.
13.
Herr HW, Donat SM: Quality control in transurethral resection of bladder tumours. BJU Int 2008; 102: 1242–1246.
14.
Mostafid AH, Palou Redorta J, Sylvester R, Witjes JA: Therapeutic options in high-risk non-muscle-invasive bladder cancer during the current worldwide shortage of bacille Calmette-Guerin. Eur Urol 2015; 67: 359–360.
15.
Charlson M, Szatrowski TP, Peterson J, Gold J: Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47: 1245–1251.
16.
Serretta V, Scalici Gesolfo C, Alonge V, Cicero G, Moschini M, Colombo R: Does the compliance to intravesical BCG differ between common clinical practice and international multicentric trials? Urol Int 2016; 96: 20–24.
17.
Hollingsworth JM, Zhang Y, Krein SL, Ye Z, Hollenbeck BK: Understanding the variation in treatment intensity among patients with early stage bladder cancer. Cancer 2010; 116: 3587–3594.
18.
Chamie K, Saigal CS, Lai J, Hanley JM, Setodji CM, Konety BR, et al: Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer 2011; 117: 5392–5401.
19.
Lebentrau S, May M, Wick AK, Roiner M, Mathew M, Gilfrich C, et al: Non-muscle invasive bladder cancer: are epicrises the “bermuda triangle” of information transfer? Cent European J Urol 2017; 70: 245–251.
20.
Mossanen M, Ingham MD, Leow JJ, Tinay I, Wang Y, Krasnow RE, et al: Exploring patterns of mitomycin C use in community practice urology. Urol Pract 2018; 5: 7–14.
21.
Reinstatler L, Schroeck FR, Hyams ES: Ensuring evidence-based practice: a study of factors associated nonuse of American Urological Association Guidelines. Urol Pract 2017; 4: 25–29.
22.
Schrag D, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB: Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst 2003; 95: 588–597.
23.
MacLennan S, Briganti A, Grimshaw JM, N'Dow J: Re: Low Adherence to Guidelines in Nonmuscle-invasive Disease. Eur Urol 2017; 71: 689.
24.
Montie JE: Guideline application and the real world. Urol Oncol 2014; 32: 377–379.
25.
Rink M, Dahlem R, Kluth L, Minner S, Ahyai SA, Eichelberg C, et al: Older patients suffer from adverse histopathological features after radical cystectomy. Int J Urol 2011; 18: 576–584.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.